Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 2/20 | 0.52 |
| ▸ | CTSV | O60911 | 9/20 | 0.49 |
| ▸ | CTSL | P07711 | 9/20 | 0.49 |
| ▸ | CTSS | P25774 | 9/20 | 0.49 |
| ▸ | CTSK | P43235 | 8/20 | 0.49 |
| ▸ | CTSB | P07858 | 7/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TLR3 | O15455 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23633238 | 0.85 | HTRA1 (0.51) | CTSVCTSLCTSSCTSKCTSB | |
| SCHEMBL23279689 | 0.81 | CTSV (0.70) | CTSVCTSLCTSSCTSKCTSB | |
| SCHEMBL23279600 | 0.81 | CTSL (0.70) | C3AR1CTSVCTSLCTSSCTSK | |
| SCHEMBL20591555 | 0.81 | CTSV (0.70) | CTSVCTSLCTSSCTSKCTSB | |
| SCHEMBL25045736 | 0.79 | CTSL (0.52) | CTSVCTSLCTSSCTSKCTSB | |
| SCHEMBL3451680 | 0.78 | FPR2 (0.49) | CTSVCTSLCTSSCTSKCTSB | |
| SCHEMBL3451686 | 0.78 | FPR2 (0.49) | CTSVCTSLCTSSCTSKCTSB | |
| SCHEMBL29981912 | 0.78 | FOLH1 (0.52) | CTSVCTSLCTSSCTSKCTSB | |
| SCHEMBL27477804 | 0.78 | CTSL (0.53) | CTSVCTSLCTSSCTSKCTSB | |
| SCHEMBL27552211 | 0.78 | CTSL (0.53) | CTSVCTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HTRA1, HTR1A, HTR1E | C3AR1 511/4885CTSV 1331/4885CTSL 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.